scholarly journals The Significance of PSA/IGF-1 Ratio in Differentiating Benign Prostate Hyperplasia from Prostate Cancer

2000 ◽  
Vol 16 (3-4) ◽  
pp. 143-146 ◽  
Author(s):  
G. Koliakos ◽  
D. Chatzivasiliou ◽  
Th. Dimopoulos ◽  
V. Trachana ◽  
K. Paschalidou ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Roc Analysis ◽  
Benign Prostate Hyperplasia ◽  
Specific Antigen ◽  
Prostatic Hyperplasia ◽  
Prostate Hyperplasia ◽  
Patients With Cancer ◽  
Free Psa ◽  
Benign Prostate

The importance of insulin-like growth factor 1 (IGF-1) in human serum for the early diagnosis of prostate cancer is controversial. The IGF-1/PSA ratio may improve the performance of prostate specific antigen (PSA) as a prostate cancer marker. IGF-1, along with PSA and free PSA concentration, was measured in the serum of 34 patients with prostate cancer and in 131 patients with benign prostatic hyperplasia (BPH). Although IGF-1 concentration did not significantly differ between the groups, PSA/IGF-1 ratio could clearly distinguish the two groups. In patients with cancer but not in patients with BPH, IGF-1 concentration correlated with PSA and free PSA. The values of PSA and free PSA correlated with each other for both groups. Receivers Operating Curve (ROC) analysis indicated a better sensitivity to specificity ratio for PSA/IGF-1 than for PSA or Free/Total (F/T) PSA.

scholarly journals Analysis of Urinary Prostate-Specific Antigen Glycoforms in Samples of Prostate Cancer and Benign Prostate Hyperplasia

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Chun-Jen Hsiao ◽  
Tzong-Shin Tzai ◽  
Chein-Hung Chen ◽  
Wen-Horng Yang ◽  
Chung-Hsuan Chen
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Benign Prostate Hyperplasia ◽  
Clinical Sample ◽  
Specific Antigen ◽  
Ion Accumulation ◽  
Detection Sensitivity ◽  
Prostate Hyperplasia ◽  
Liquid Chromatography Tandem Mass ◽  
Benign Prostate

Glycans of prostate-specific antigen (PSA) in prostate cancer were found to be different from that in benign disease. It is difficult to analyze heterogeneous PSA glycoforms in each individual specimen because of low protein abundance and the limitation of detection sensitivity. We developed a method for prostate cancer diagnosis based on PSA glycoforms. Specific glycoforms were screened in each clinical sample based on liquid chromatography-tandem mass spectrometry with ion accumulation. To look for potential biomarkers, normalized abundance of each glycoform in benign prostate hyperplasia (BPH) and in prostate cancer was evaluated. The PSA glycoform, Hex5HexNAc4NeuAc1dHex1, and monosialylated, sialylated, and unfucosylated glycoforms differed significantly between the prostate cancer and BPH samples. The detection sensitivity (87.5%) and specificity (60%) for prostate cancer identification are higher than those of the serum PSA marker. As low as 100 amol PSA could be detected with the ion accumulation method which has not been reported before. The improved detection specificity can help reduce unnecessary examinations.

scholarly journals The Combination of Human Glandular Kallikrein and Free Prostate-specific Antigen (PSA) Enhances Discrimination Between Prostate Cancer and Benign Prostatic Hyperplasia in Patients with Moderately Increased Total PSA

1999 ◽  
Vol 45 (11) ◽  
pp. 1960-1966 ◽  
Author(s):  
Angeliki Magklara ◽  
Andreas Scorilas ◽  
William J Catalona ◽  
Eleftherios P Diamandis
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Prostate Specific Antigen ◽  
Prostatic Carcinoma ◽  
Specific Antigen ◽  
Area Under The Curve ◽  
Prostatic Hyperplasia ◽  
Free Psa ◽  
Glandular Kallikrein ◽  
Total Psa

Abstract Background: Prostate-specific antigen (PSA) is the most reliable tumor marker available and is widely used for the diagnosis and management of prostate cancer. Unfortunately, PSA cannot distinguish efficiently between benign and malignant disease of the prostate, especially within the range of 4–10 μg/L. Among the refinements developed to enhance PSA specificity is the free/total PSA ratio, which is useful in discriminating between the two diseases within the diagnostic “gray zone”. Recent data indicate that human glandular kallikrein (hK2), a protein with high homology to PSA, may be an additional serum marker for the diagnosis and monitoring of prostate cancer. Methods: We analyzed 206 serum samples (all before treatment was initiated) from men with histologically confirmed benign prostatic hyperplasia (n = 100) or prostatic carcinoma (n = 106) with total PSA in the range of 2.5–10 μg/L. Total and free PSA and hK2 were measured with noncompetitive immunological procedures. Statistical analysis was performed to investigate the potential utility of the various markers or their combinations in discriminating between benign prostatic hyperplasia and prostatic carcinoma. Results: hK2 concentrations were not statistically different between the two groups of patients. There was a strong positive correlation between hK2 and free PSA in the whole patient population. hK2/free PSA ratio (area under the curve = 0.69) was stronger predictor of prostate cancer than the free/total PSA ratio (area under the curve = 0.64). At 95% specificity, the hK2/free PSA ratio identified 30% of patients with total PSA between 2.5–10 μg/L who had cancer. At 95% specificity, the hK2/free PSA ratio identified 25% of patients with total PSA between 2.5 and 4.5 μg/L who had cancer. Conclusions: Our data suggest that hK2 in combination with free and total PSA can enhance the biochemical detection of prostate cancer in patients with moderately increased total PSA concentrations. More specifically, the hK2/free PSA ratio appears to be valuable in identifying a subset of patients with total PSA between 2.5 and 4.5 μg/L who have high probability of cancer and who should be considered for biopsy.

scholarly journals Detection of Tear Biomarkers for Future Prostate Cancer Diagnosis

2010 ◽  
Vol 3 (1) ◽  
pp. 26-29 ◽  
Author(s):  
Yong Li
Keyword(s):  
Prostate Cancer ◽  
Benign Prostate Hyperplasia ◽  
Specific Antigen ◽  
Clinical Proteomics ◽  
Prostate Hyperplasia ◽  
Psa Test ◽  
Diagnosis And Prognosis ◽  
Novel Biomarkers ◽  
Unique Source ◽  
Benign Prostate

Prostate cancer (CaP) continues to be the second leading cause of cancer-specific death in men in Western countries. The marker currently used for CaP detection is an increase in serum prostate specific antigen (PSA). However, the PSA test may give false positive or negative information and does not allow the differentiation of benign prostate hyperplasia (BPH), non-aggressive CaP and aggressive CaP. Tears are a unique source of body fluid and contain proteins, peptides, mucins and lipids, which is useful for studying clinical proteomics. Advances in the field of proteomics have greatly enhanced the study of tears, with a greater number of proteins now being identified in tears. Identification of novel biomarkers in tear is a new area of development. Modern advances in the field of proteomic techniques hold the promise of providing the clinical oncologists with new tools to find novel CaP biomarkers for early diagnosis and prognosis.

scholarly journals PREPARASI PEREAKSI KIT IMMUNORADIOMETRlCASSAY FREE PROSTATE SPECIFIC ANTIGEN UNTUK DETEKSI KANKER PROSTAT

2013 ◽  
Vol 15 (2) ◽  
pp. 14-24
Author(s):  
Puji Widayati ◽  
Gina Mondrida ◽  
Sri Setiyowati ◽  
Agus Ariyanto ◽  
V. Yulianti Susilo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Prostate Gland ◽  
Specific Antigen ◽  
Prostatic Hyperplasia ◽  
Free Condition ◽  
Free Psa ◽  
Prostate Enlargement ◽  
Assay Design ◽  
Benign Prostate

Prostate Specific Antigen (PSA) is a glycoprotein with a molecular weight of approximately 34,000 daltons serine protease secreted exclusively by prostatic epithelial cells that lining acini and prostate gland. Increased of PSA levels can be caused by prostate cancer or benign prostate enlargement (benign prostatic hyperplasia, BPH). PSA in the blood was found in the free condition (free PSA) and most of the bound protein (complexed-PSA, c-PSA). Measuring levels of PSA was found in the blood can be done by several methods such as by immunoradiometricassay (IRMA) methods or ELISA methods. IRMA method is one of immunoassay techniques using radionuclides ,/' 125 oJ I as a tracer, so the sample in small 13 quantity can be detected The purpose of this study was obtained PSA reagent kit that includes 1251labeled PSA as a tracer, PSA coated tube and PSA standard that requirements of the kit, then it can be optimized assay design, that eventually PSA reagent kit can be used for early detection of prostate cancer. It has been done labeling of Mab PSA using 125 1with reaction time was 90 seconds, amount of PSA MAb was 75 ugram and the activity of Na_ 125I was 1000 flCi. Preaparation of PSA coated tube using 0.05 M Na2C03 solution, at pH: 9.6 with volume was 250 ml., standard PSA with 0.025 Mphosphate buffer at pH 7.4 containing 5% BSA and 0.1% NaN3, and resulting at 1,25% and 14,12% respectively of NSB and BIT that requirement of the kit.Keywords: Prostate cancer, PSA, IRMA,NSB, Maximum Binding

scholarly journals Periodontal disease and risk of benign prostate hyperplasia: a cross-sectional study

2019 ◽  
Vol 6 (1) ◽  
Author(s):  
Lan Wu ◽  
Bing-Hui Li ◽  
Yun-Yun Wang ◽  
Chao-Yang Wang ◽  
Hao Zi ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Periodontal Disease ◽  
Subgroup Analysis ◽  
Benign Prostate Hyperplasia ◽  
Prostate Volume ◽  
Prostatic Hyperplasia ◽  
Health Examination ◽  
Control Analysis ◽  
Prostate Hyperplasia ◽  
Benign Prostate

Abstract Background Both periodontal disease and benign prostatic hyperplasia are age-related diseases that affect millions of people worldwide. Hence, this study aimed to investigate the association between periodontal disease and the risk of benign prostatic hyperplasia. Methods A total of 4930 participants were selected from an available health examination that was carried out in 2017, only males were considered for further analysis. All eligible males were divided into benign prostatic hyperplasia and normal groups, the benign prostatic hyperplasia group was then divided into prostate volume ≤ 60 g and > 60 g subgroups; all their periodontal status was extracted and then into normal (CPI score of 0), periodontal disease (CPI score between 1 and 4), and periodontitis (CPI score between 3 and 4) groups. The correlation between periodontal disease and benign prostatic hyperplasia was investigated using logistic regression analyses and greedy matching case-control analysis. Subgroup analysis based on prostate volume was also performed. All analyses were conducted with SAS 9.4 software. Results A total of 2171 males were selected for this analysis. The presence of periodontal disease significantly increased the risk of benign prostatic hyperplasia by 1.68 times (OR = 1.68, 95% CI: 1.26–2.24), and individuals with periodontitis showed a higher risk (OR = 4.18, 95% CI: 2.75–6.35). In addition, among matched cases and controls, this association remained robust (periodontal disease: OR = 1.85, 95% CI: 1.30–2.64; periodontitis: OR = 4.83, 95% CI: 2.57–9.07). Subgroup analysis revealed that periodontal disease significantly increased benign prostate hyperplasia risk as well (for prostate volume ≤ 60 g: OR = 1.64, 95% CI: 1.22–2.20; for volume > 60 g: OR = 2.17, 95% CI: 1.04–4.53), and there was a higher risk in the group with a prostate volume greater than 60 g. Conclusion Periodontal disease is significantly and positively associated with an increased risk of benign prostatic hyperplasia. Further validation studies should be performed to explore the relationship between periodontal treatment and benign prostate hyperplasia.

scholarly journals Urinary PSA in monitoring of patients with prostate cancer

2012 ◽  
Vol 59 (1) ◽  
pp. 57-60 ◽  
Author(s):  
Tomislav Pejcic ◽  
V. Dimitrijevic ◽  
Jovan Hadzi-Djokic
Keyword(s):  
Prostate Cancer ◽  
Benign Prostate Hyperplasia ◽  
Specific Antigen ◽  
Radical Retropubic Prostatectomy ◽  
Secretory Cells ◽  
Prostate Hyperplasia ◽  
Retropubic Prostatectomy ◽  
Androgen Suppression ◽  
Antiandrogen Therapy ◽  
Benign Prostate

Objective: To estimate the value of urinary prostate specific antigen (uPSA) determination in the monitoring of prostate cancer (PCa) patients. Material and methods: From January 2001 to December 2011, uPSA was determined in 397 patients. There were 265 patients with benign prostate, 19 with prostatitis and 113 with prostate cancer. Radical retropubic prostatectomy (RRP) was performed at 65 patients, while 48 patients had PCa received antiandrogen therapy. Results: Average uPSA value in the patients with benign prostate hyperplasia (BPH) was 190.8+184.2 ng/mL. Average uPSA in the patients with PCa was 287.5+303.4 ng/ml and it was not significantly different from BPH group. The average uPSA in the prostatitis group was 113.1+148.5 ng/mL, and 16.4+36.7 ng/mL in the post RRP group. During antiandrogen therapy, uPSA and PSA correlated significantly (r=0.49). Conclusion: The uPSA level reflects the response of normal prostatic and urethral secretory cells on total androgen activity. The uPSA level cannot distinguish the cases with BPH and cases with PCa. In addition, in the patients after RRP, uPSA reflects local urethral PSA production and has no role in the diagnosis of PCa recurrence. However, uPSA is better indicator of androgen suppression than testosterone (T), as it reflects the effect of suppression of all androgens, not only T.

scholarly journals Study on Estimation of Serum Prostate Specific Antigen Level and Prostate Volume with Trans-Abdominal Ultrasonography Finding in Benign Prostate Hypertrophy at Tertiary Care Hospital : A Cross Sectional Descriptive Study

2021 ◽  
Vol 6 (2) ◽  
pp. 1556-1560
Author(s):  
Chandra Prakash Gaire
Keyword(s):  
Prostate Specific Antigen ◽  
Benign Prostate Hyperplasia ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Prostatic Hyperplasia ◽  
Prostate Specific Antigen Level ◽  
Age Group ◽  
Antigen Level ◽  
Prostate Hyperplasia ◽  
Benign Prostate

Introduction: The periurethral and transition zones of the prostatic gland develop benign prostatic hyperplasia and represent an inevitable phenomenon for the ageing male population. Prostatic specific antigen, is a serine protease, level rises in the blood if the barrier between thelining epithelium and the blood stream is damaged. Benign prostatic hyperplasia, prostatic carcinoma and prostatitis are three common diseases where PSA in the serum is raised. Prostate volume also increases according to age, which can be estimated by trans-abdominal ultrasonography. Objective: The aim of the study is to estimate the PSA level in blood and its relationship with prostate volume in benign prostatic hyperplasia patients. Methodology: It is a descriptive cross-sectional study which was carried out between a periods of 1st April 2018 to 31st March 2019 at Birat Medical College Teaching Hospital. All the patients diagnosed with benign prostate hyperplasia at the department of urology were included in the study. Blood samples of patients were analyzed for Prostate specific antigen level estimation by chemiluminescence immunosorbent assay. Prostatic volume of the patients was measured by Transabdominal ultrasound technique. Data were entered and analyzed in Microsoft Excel. Results: A total of 68 patients were diagnosed with benign prostate hyperplasia. The mean age of the patients was 61.8±12.3 years. The maximum number 23 of patients with BPH was there in age group 51-60. The maximum no of patients 38 were having their PSA level between the range of 4.0-10.0 ng/ml. The maximum no of patients 28 was having Prostate volume in the range of 40-60 gm. The maximum number of patients 31 was having diabetes mellitus as a co-morbid association. The maximum mean PSA level and prostate volume in the patients were observed in age group >80 years,which was 20.1±8.6 ng/ml and >80 gm respectively. Conclusion: The prostate specific antigen level and prostate volume both increase in advance age group of patients suffering with benign prostate hyperplasia.

Sign in / Sign up

Export Citation Format

Share Document